Cargando…
Machine Learning to Understand the Immune-Inflammatory Pathways in Fibromyalgia
Fibromyalgia (FM) is a chronic syndrome characterized by widespread musculoskeletal pain, and physical and emotional symptoms. Although its pathophysiology is largely unknown, immune-inflammatory pathways may be involved. We examined serum interleukin (IL)-6, high sensitivity C-reactive protein (hs-...
Autores principales: | Andrés-Rodríguez, Laura, Borràs, Xavier, Feliu-Soler, Albert, Pérez-Aranda, Adrián, Rozadilla-Sacanell, Antoni, Arranz, Belén, Montero-Marin, Jesús, García-Campayo, Javier, Angarita-Osorio, Natalia, Maes, Michael, Luciano, Juan V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747258/ https://www.ncbi.nlm.nih.gov/pubmed/31470635 http://dx.doi.org/10.3390/ijms20174231 |
Ejemplares similares
-
Cost-utility and biological underpinnings of Mindfulness-Based Stress Reduction (MBSR) versus a psychoeducational programme (FibroQoL) for fibromyalgia: a 12-month randomised controlled trial (EUDAIMON study)
por: Feliu-Soler, Albert, et al.
Publicado: (2016) -
Cost–Utility of Mindfulness-Based Stress Reduction for Fibromyalgia versus a Multicomponent Intervention and Usual Care: A 12-Month Randomized Controlled Trial (EUDAIMON Study)
por: Pérez-Aranda, Adrián, et al.
Publicado: (2019) -
Psychometric Properties of the Cognitive Emotion Regulation Questionnaire (CERQ) in Patients with Fibromyalgia Syndrome
por: Feliu-Soler, Albert, et al.
Publicado: (2017) -
Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost–utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)
por: Colomer-Carbonell, Ariadna, et al.
Publicado: (2022) -
Fifteen Years Controlling Unwanted Thoughts: A Systematic Review of the Thought Control Ability Questionnaire (TCAQ)
por: Feliu-Soler, Albert, et al.
Publicado: (2019)